3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Vascular Diseases
1
Respiratory Tract Diseases
1
Pulmonary Embolism
1
Neoplasms
1
Lung Diseases
1
Embolism and Thrombosis
1
Embolism
1
Disease
1
Cardiovascular Diseases
1
Interventions
Carboplatin
10
Paclitaxel
5
Nivolumab
4
Pemetrexed
3
Cisplatin
3
atezolizumab
2
apatinib
2
Surveys and Questionnaires
2
One-Lung Ventilation
2
Ipilimumab
2
Blood Specimen Collection
2
Bevacizumab
2
zimberelimab
1
toripalimab
1
spartalizumab
1
sitravatinib
1
sintilimab
1
sacituzumab govitecan
1
pembrolizumab
1
lorlatinib
1
cemiplimab
1
camrelizumab
1
Vital Signs
1
Vinorelbine
1
Tyrosine Kinase Inhibitors
1
Tomography, Emission-Computed, Single-Photon
1
Temozolomide
1
Telescopes
1
Talc
1
Saline Solution
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Lung Diseases
×
4-((1,4,8,11-tetraazacyclotetradec-1-yl)methyl)benzoic acid
×
Clear all
NCT04657120
2025-12-23
HYDRA
Leiden University Medical Center
Phase NA
Completed
698 enrolled